A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2018
At a glance
- Drugs Diacerein (Primary) ; Clobetasol
- Indications Bullous pemphigoid
- Focus Adverse reactions; Proof of concept
- Sponsors TWi Biotechnology
- 26 Oct 2018 Planned End Date changed from 31 May 2018 to 1 May 2019.
- 26 Oct 2018 Planned primary completion date changed from 15 May 2018 to 1 Mar 2019.
- 20 Sep 2017 New trial record